Kevin Reilly Sells 2,932 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

by · The Cerbat Gem

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS – Get Free Report) Director Kevin Reilly sold 2,932 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $25.13, for a total value of $73,681.16. Following the transaction, the director directly owned 5,368 shares of the company’s stock, valued at approximately $134,897.84. The trade was a 35.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Price Performance

NASDAQ KMTS traded down $0.50 on Thursday, hitting $23.57. The company had a trading volume of 310,496 shares, compared to its average volume of 240,413. The company has a market capitalization of $1.38 billion, a PE ratio of -9.74 and a beta of 0.62. The company’s fifty day moving average price is $25.42 and its 200-day moving average price is $22.71. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 4.41. Kestra Medical Technologies, Ltd. has a 12-month low of $17.34 and a 12-month high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) last posted its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%.The firm had revenue of $28.64 million during the quarter. As a group, analysts predict that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current year.

Hedge Funds Weigh In On Kestra Medical Technologies

Several institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. raised its stake in shares of Kestra Medical Technologies by 43.5% during the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after purchasing an additional 474 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Kestra Medical Technologies by 148.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after buying an additional 1,638 shares during the period. Daiwa Securities Group Inc. acquired a new position in Kestra Medical Technologies during the fourth quarter worth $72,000. Brown Brothers Harriman & Co. lifted its holdings in Kestra Medical Technologies by 26.8% in the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after acquiring an additional 656 shares during the period. Finally, New York State Common Retirement Fund purchased a new position in shares of Kestra Medical Technologies in the 2nd quarter valued at about $93,000.

Analyst Upgrades and Downgrades

A number of research firms recently commented on KMTS. Oppenheimer assumed coverage on Kestra Medical Technologies in a report on Tuesday, July 21st. They issued a “market perform” rating on the stock. JPMorgan Chase & Co. assumed coverage on shares of Kestra Medical Technologies in a research note on Monday, August 10th. They issued an “overweight” rating and a $30.00 price target for the company. Wolfe Research set a $30.00 target price on shares of Kestra Medical Technologies in a research note on Wednesday, July 15th. Weiss Ratings downgraded Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 31st. Finally, BTIG Research reissued a “buy” rating and issued a $32.00 price target on shares of Kestra Medical Technologies in a research report on Wednesday, September 2nd. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Kestra Medical Technologies currently has a consensus rating of “Hold” and a consensus price target of $28.14.

View Our Latest Report on KMTS

About Kestra Medical Technologies

(Get Free Report)

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.

Further Reading